The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models

BACKGROUND: Despite initial response to platinum-based chemotherapy and PARP inhibitor therapy (PARPi), nearly all recurrent high-grade serous ovarian cancer (HGSC) will acquire lethal drug resistance; indeed, ~15% of individuals have de novo platinum-refractory disease. OBJECTIVES: To determine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Gwo Yaw, Vandenberg, Cassandra J., Lim, Ratana, Christie, Elizabeth L., Garsed, Dale W., Lieschke, Elizabeth, Nesic, Ksenija, Kondrashova, Olga, Ratnayake, Gayanie, Radke, Marc, Penington, Jocelyn S., Carmagnac, Amandine, Heong, Valerie, Kyran, Elizabeth L., Zhang, Fan, Traficante, Nadia, Huang, Ruby, Dobrovic, Alexander, Swisher, Elizabeth M., McNally, Orla, Kee, Damien, Wakefield, Matthew J., Papenfuss, Anthony T., Bowtell, David D. L., Barker, Holly E., Scott, Clare L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666702/
https://www.ncbi.nlm.nih.gov/pubmed/38028140
http://dx.doi.org/10.1177/17588359231208674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666702/
https://www.ncbi.nlm.nih.gov/pubmed/38028140
http://dx.doi.org/10.1177/17588359231208674

Ejemplares similares